Agranulocytosis: Difference between revisions
Nazia Fuad (talk | contribs) |
Nazia Fuad (talk | contribs) |
||
| Line 60: | Line 60: | ||
==Differentiating Agranulocytosis from Other Diseases== | ==Differentiating Agranulocytosis from Other Diseases== | ||
Consider the following differential when evaluating a patient with agranulocytosis: | Consider the following differential when evaluating a patient with agranulocytosis: | ||
* | * Bacterial sepsis | ||
* | * Aplastic anemia | ||
* | * Acute myloid | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Revision as of 14:56, 25 September 2018
|
WikiDoc Resources for Agranulocytosis |
|
Articles |
|---|
|
Most recent articles on Agranulocytosis Most cited articles on Agranulocytosis |
|
Media |
|
Powerpoint slides on Agranulocytosis |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Agranulocytosis at Clinical Trials.gov Trial results on Agranulocytosis Clinical Trials on Agranulocytosis at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Agranulocytosis NICE Guidance on Agranulocytosis
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Agranulocytosis Discussion groups on Agranulocytosis Patient Handouts on Agranulocytosis Directions to Hospitals Treating Agranulocytosis Risk calculators and risk factors for Agranulocytosis
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Agranulocytosis |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Daniel A. Gerber, M.D. [2] Nazia Fuad M.D.
Synonyms and Keywords: Agranulosis, granulocytopenia, neutropenia
Overview
Agranulocytosis is a hematological disorder characterized by the acute-onset of severe neutropenia. Neutrophils - a subset of white blood cell - normally make up 50-70% of circulating white blood cells and serve as the primary defense against infections. Hence, patients with neutropenia are more susceptible to infections, mainly bacterial; without prompt medical attention, the condition is often life-threatening. Similar to severe neutropenia in the setting of infection, cases related to cytotoxic chemotherapy, hematopoietic stem cell transplant, or other causes of bone marrow suppression are considered a medical emergency.
Agranulocytosis is defined as severe neutropenia with an absolute neutrophil count (ANC) <500 cells/microliter.
While agranulocytosis technically refers to a reduction in all cells in the leukocyte lineage (neutrophils, eosinophils, and basophils), the vast majority of cases refer to neutropenia as neutrophils constitute the majority of leukocytes and the primary defense against infection.
Historical Perspective
- Agranulocytosis was first noted around the start of the 20th century on review of blood cell differentials described in patients with lupus, other autoimmune disorders, and with various drug toxicities.[1]
Classification
Agranulocytosis is often used interchangeably with severe neutropenia. Calculated based on complete blood count differential, agranulocytosis is loosely defined as an absolute neutrophil count (ANC) less than 500, 200, or 100 cells per microliter, with mild and moderate neutropenia defined below.[2] The ANC is calculated by multiplying the total white blood cell (WBC) count by the percentage of neutrophils (including both mature neutrophils and band forms).
- Mild Neutropenia: ANC 1,000-1500 cells/microliter
- Moderate Neutropenia: ANC 500-1000 cells/microliter
- Severe Neutropenia or Agranulocytosis: ANC <500 cells/microliter
This distinction is important diagnostically and prognostically. Patients with ANC <500 cells/microliter are at a markedly increased risk for severe infections and those <100 cells/microliter have just over a 3-fold increased risk of mortality[2] Importantly, due to severely limited neutrophil activity an inflammatory response, these patients may present with a fever absent additional localizing signs of infection.
Pathophysiology
Agranulocytosis develops as a result of the following mechanisms:[3]
- Immune mediated destruction of granulocytes
- The drugs or its active metabolite act as hapten, and binds to neutrophil membrane.
- Autoantibodies are produced as a result of this binding.
- This results in destruction of sensetized neutrophils by phagocytosis.
- Most common drugs are, propylthiouracil, amodiaquine , mono-desethyl amodiaquine, and flecainide
- Direct damage of granulocytes
- Some drugs releases chemically active metabolites.
- These metabolites bind to cytoplasmic proteins or proteins in the nucleus.
- This results in direct toxicity and destruction of granulocytes.
- Chlorpromazine. dapsone, clozapine and procainamide are few examples of the drugs.
- Granulocytes oxidize clozapine releasing nitrenium ions.[4]
- Nitrenium ions bind irreversibly to granulocytes and its precursor cells resulting in toxic destruction of these cells.
Causes
Agranulocytosis can be congenital or acquired. Common causes of acquired agranulocytosis include:[2][5]
- Medications
- Chemotherapy
- Bone marrow transplant
- Systemic lupus erythematosus(SLE)
- Rheumatoid arthritis
- HIV
- Hepatitis
- Leukemia
- Myelodysplasia
Differentiating Agranulocytosis from Other Diseases
Consider the following differential when evaluating a patient with agranulocytosis:
- Bacterial sepsis
- Aplastic anemia
- Acute myloid
Epidemiology and Demographics
- Agranulocytosis is extremly rare condition
- The overall incidence rate is 7.2 per million per year[6]
- It can occur in all races and any age group
- The acquired type of agraulocytosis is more common in older individuals
- Inherited type is commonly seen in children.
- The risk of agranulocytosis is seen higher in women[7]
Risk Factors
Risk factors for agranulocytosis include:
- Acquired conditions
- Medications[8]
- Infectious mononucleosis[9]
- Combination therapy with ACE inhibitors and interferon[10]
- Cytotoxic chemotherapy
- Hematologic malignancies
- Autoimmune disorders
- Genetic susceptibility
- Association between HLA-B38, DQW3 haplotype and clozapine induced agranulocytosis is seen in Ashkenazi Jews[11]
- HLA DRB1*08032 allele has a strong suseptibility to methimazole induced agranulocytosis[12]
Screening
There are no routine screening recommendations for agranulocytosis. It is typically identified incidentally on routine blood work or while monitoring after cytotoxic therapy.[13]
Natural History, Complications, and Prognosis
Natural History
- Neutropenia, and progression to agranulocytosis, occurs in either a dose-dependent or idiosyncratic process dependent upon the etiology.
- Neutropenia caused by cytotoxic chemotherapy or malignant bone marrow infiltration is typically dose-dependent or related to tumor burden, as opposed to
- Idiosyncratic, and immune-mediated neutropenia occur independently.
Complications
The major complications of agranulocytosis are as follows[14]
Prognosis
The negative prognostic factors for agranulocytosis are:[15]
- Neutrophil count at the time of diagnosis <0.1 × 109/l
- Age > 65yrs
- Advancement in to severe infections like septic shock, bacteremia
- Pre existance of systemic infections, renal, cardiac and respiratory diseases.
History and Symptoms
History
History of patients with agranulocytosis should focus on any history of:
Symptoms
Common symptoms include:
- Fever
- Frequent infections
- Unusual redness, pain, or swelling around a wound
- Mouth ulcers
- Diarrhea
- Burning sensation when urinating
- Sore throat
- Shortness of breath
- Shaking chills
Physical Examination
Common signs of agranulocytosis may include:
- Fever
- Tachycardia
- Hypotension
- Tachypnea
- Hypoxia
- Jaundice
- Wheezes
- rales
- Joint swelling or deformity
- Rashes
Laboratory Findings
Treatment
Medical Therapy
- Discontinuation of the offending agent
- Identifying and removing the offending agents
- It takes about 1-3 weeks for neutropenia to resolve after stopping the offending drug
- Treat the associated infections and conditions
- In cases of febrile neutropenia, empiric antibiotics should be administered intravenously as early as possible[16]
- Before starting the antibiotics, blood, urine and sputum cultures should be withdrawn
- Antibiotic coverage should be bactericidal for most common pathogens[17][18][19]
- Central venous catheters and other indwelling devices should be removed when possible if there is suspicion for infection or with positive blood cultures.
- Use of granulocyte-colony stimulating factor
- Granulocyte-colony stimulating factor G-CSF has shown excellent results in patients with drug induced agranulocytosis and severe infection.
- It is very beneficial in patiets with neutropenia secondry to chemotherapy
- Immune suppression
- In neutropenia with autoimmune diseases, prednisone is used for immune suppression
- Bone marrow transplant
- When other treatments do not work, bone marrow transplant is an option
- It is more successful in patients aged<40 yrs and with good health.
Surgery
There are no surgical treatments for agranulocytosis. In patients with neutropenic fever, surgical intervention may be necessary depending on the source of infection.[13]
Prevention
Prevention of agranulocytosis is dependent upon:
- Avoiding certain medications
- Treatment of underlying conditions
- Occasionally, when agranulocytosis is anticipated, such as in the setting of cytotoxic chemotherapy, recombinant G-CSF (granulocyte-colony stimulating factor) can be considered to speed myeloid reconstitution
See also
References
- ↑ Dameshek W. (1944). "Leukopenia and Agranulocytosis". Oxford University Press. 1: 841–52. Text "NLM ID 39120200R" ignored (help)
- ↑ 2.0 2.1 2.2 Andersohn F, Konzen C, Garbe E. (2007). "Systematic review: agranulocytosis induced by nonchemotherapy drugs". Ann Internal Med. 146(9): 657–65. Text "PMID 17470834" ignored (help)
- ↑ Pontikoglou, Charalampos; Papadaki, Helen A. (2010). "Idiosyncratic Drug-Induced Agranulocytosis: The Paradigm of Deferiprone". Hemoglobin. 34 (3): 291–304. doi:10.3109/03630269.2010.484791. ISSN 0363-0269.
- ↑ Uetrecht, Jack; Zahid, Nasir; Tehim, Ashik; Mim Fu, J; Rakhit, Suman (1997). "Structural features associated with reactive metabolite formation in clozapine analogues". Chemico-Biological Interactions. 104 (2–3): 117–129. doi:10.1016/S0009-2797(97)00017-3. ISSN 0009-2797.
- ↑ Andersohn, Frank; Konzen, Christine; Garbe, Edeltraut (2007). "Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs". Annals of Internal Medicine. 146 (9): 657. doi:10.7326/0003-4819-146-9-200705010-00009. ISSN 0003-4819.
- ↑ Strom, Brian L. (1992). "Descriptive Epidemiology of Agranulocytosis". Archives of Internal Medicine. 152 (7): 1475. doi:10.1001/archinte.1992.00400190095018. ISSN 0003-9926.
- ↑ Alvir, Jose Ma. J.; Lieberman, Jeffrey A.; Safferman, Allan Z.; Schwimmer, Jeffrey L.; Schaaf, John A. (1993). "Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States". New England Journal of Medicine. 329 (3): 162–167. doi:10.1056/NEJM199307153290303. ISSN 0028-4793.
- ↑ Andrès E, Zimmer J, Affenberger S, Federici L, Alt M, Maloisel F. (2006). "Idiosyncratic drug-induced agranulocytosis: Update of an old disorder". Eur J Intern Med. 17 (8): 529–35. Text "pmid 17142169" ignored (help)
- ↑ Levy M, Kelly JP, Kaufman DW, Shapiro S (October 1993). "Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study". Ann. Hematol. 67 (4): 187–90. PMID 8218540.
- ↑ Casato, Milyia; Pucillo, Leopoldo P.; Leoni, Marco; di Lullo, Luca; Gabrielli, Armando; Sansonno, Domenico; Dammacco, Franco; Danieli, Giovanni; Bonomo, Lorenzo (1995). "Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: Evidence for a synergistic hematologic toxicity". The American Journal of Medicine. 99 (4): 386–391. doi:10.1016/S0002-9343(99)80186-7. ISSN 0002-9343.
- ↑ Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ (November 1995). "The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups". Blood. 86 (10): 3835–40. PMID 7579351.
- ↑ Tamai, Hajime (1996). "Association between the DRB1*08032 Histocompatibility Antigen and Methimazole-Induced Agranulocytosis in Japanese Patients with Graves Disease". Annals of Internal Medicine. 124 (5): 490. doi:10.7326/0003-4819-124-5-199603010-00005. ISSN 0003-4819.
- ↑ 13.0 13.1 Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. (2011). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america". Clin Infect Dis. 52 (4): e56–95. PMID 21258094.
- ↑ Andrès, Emmanuel; Maloisel, Frédéric; Zimmer, Jacques (2010). "The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis". British Journal of Haematology. doi:10.1111/j.1365-2141.2010.08104.x. ISSN 0007-1048.
- ↑ Andrès, Emmanuel; Maloisel, Frédéric; Zimmer, Jacques (2010). "The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis". British Journal of Haematology. doi:10.1111/j.1365-2141.2010.08104.x. ISSN 0007-1048.
- ↑ Tesfa, Daniel; Keisu, Marianne; Palmblad, Jan (2009). "Idiosyncratic drug-induced agranulocytosis: Possible mechanisms and management". American Journal of Hematology. 84 (7): 428–434. doi:10.1002/ajh.21433. ISSN 0361-8609.
- ↑ Schimpff S, Satterlee W, Young VM, Serpick A (1971). "Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia". N Engl J Med. 284 (19): 1061–5. PMID 4994878.
- ↑ Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006). "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock". Crit Care Med. 34 (6): 1589–96. PMID 16625125.
- ↑ Rosa RG, Goldani LZ. (2014). "Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia". Antimicrob Agents Chemother. 58 (7): 3799–803. PMID 24752269.